In the study of januvia as add-on combination therapy with metformin and rosiglitazone table 1 , through week 54 the adverse reactions reported regardless of investigator assessment of causality in 5 of patients treated with januvia and more commonly than in patients treated with placebo were upper respiratory tract infection januvia, 15.
Continue reading→